{"id":435,"date":"2025-02-10T14:31:47","date_gmt":"2025-02-10T14:31:47","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=435"},"modified":"2025-02-10T14:31:47","modified_gmt":"2025-02-10T14:31:47","slug":"stampede2","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=435","title":{"rendered":"STAMPEDE2"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer<\/strong><\/h2>\n\n\n\n
Trial Summary:<\/strong><\/h5>\n\n\n\n

Studying Treatments in patients receiving androgen deprivation therapy (ADT) and androgen receptor signalling inhibitors (ARSI) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd<\/sup> multi-arm multi-stage randomised controlled trial (STAMPEDE2)<\/p>\n\n\n\n

Comparison S Prostate SABR\/CRT QA summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n

\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>1 case per centre from the PI, to cover prostate and pelvic nodes. Streamlined (per PI) via NIHR prostate trials.<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 prostate SBRT case and 1 prostate and pelvic nodes CRT case per centre, subject to streamlining.
\nNew benchmark only if centre has changed technique\/equipment since (please discuss process with RTTQA contact)<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective \/ Retrospective outlining and planning case reviews per treatment arm to be advised by RTTQA contact<\/td>\n<\/tr>\n
Data collection<\/td><\/td><\/td>\n<\/tr>\n
Dosimetry <\/td>During accrual<\/td>\"\"<\/td>Subject to streamlining via audit from clinical trial QA groups and UK dosimetry audit network groups<\/td>\n<\/tr>\n
QA Streamlining<\/td>All activities<\/td>\"\"<\/td>PACE-A\/B\/C, PACE-NODES, PEARLS, PIVOTALboost<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n
Comparison S Oligomet SABR QA summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA or SABR QA programmes, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>2024 SABR QA Programme: FQ required<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>All centres should already have \u22652 clinicians approved through streamlining or cascade training. Benchmark only if centre has <2 clinicians accredited (1 case per anatomical site)<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>All centres should already be credentialed through streamlining. Benchmark only if centre has changed technique\/equipment since (please discuss process with RTTQA contact)<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective contouring: 1st patient per clinician, per anatomical site, subject to streamlining.
\nProspective planning: 1st patient per anatomical site, subject to streamlining.
\nRetrospective: N\/A<\/td>\n<\/tr>\n
Data collection<\/td><\/td><\/td>\n<\/tr>\n
Dosimetry <\/td>Pre-accrual Lung or Spine SABR audits<\/td>\"\"<\/td>Lung audit: bone and node only
\nSpine audit: bone, node and spine
\nSubject to streamlining<\/td>\n<\/tr>\n
QA Streamlining<\/td>All activities<\/td>\"\"<\/td>CtE, SEP, HALT, TRAP, SARON, STAR-TRAP, ATLANTA, SOPRANO <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact: <\/strong>rmh-tr.stampede2.rtqa@nhs.net<\/a><\/p>\n\n\n\n

Overall Co-Chief Investigators:<\/strong> Professor Nick James, Professor Gert Attard<\/p>\n\n\n\n

Comparison S Chief Investigators:<\/strong> Professor Nick van As, Dr Hoda Abdel-Aty<\/p>\n\n\n\n

Sponsor:<\/strong> MRC University College London mrcctu.stampede2@ucl.ac.uk<\/a><\/p>\n\n\n\n

Funder: <\/strong>CRUK, Novartis\/AAA, Janssen Pharmaceutica NV, UKRI MRC<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Trial Summary: Studying Treatments in patients receiving androgen […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-435","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=435"}],"version-history":[{"count":5,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/435\/revisions"}],"predecessor-version":[{"id":460,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/435\/revisions\/460"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}